Vifor Pharma to acquire Inositec

Vifor Pharma has announced the acquisition of Inositec AG, a Swiss start-up, developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders. Inositec purchase price includes an upfront payment of CHF 20 million and success based clinical earn-out payments.

Inositec’s lead vascular calcification inhibitor, INS-3001, is being developed to treat indications of high unmet medical need and has obtained approval for its phase-I trial, with the first healthy volunteer to be dosed on November 30, 2021. If successful, the plan is to initiate two phase-II programs in 2023, one in non-dialysis CKD patients suffering from PAD, and a separate trial in patients suffering from AVS, a serious condition whereby the aortic valves calcify to the extent that surgical intervention is the only available option.

> Zum Beitrag auf Startupticker